Get the Stockscreener App
8.17
4.34%
0.34
After Hours:
7.91
-0.26
-3.18%
Dyne Therapeutics Inc stock is traded at $8.17, with a volume of 1.32M.
It is up +4.34% in the last 24 hours and down -33.63% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$7.83
Open:
$7.82
24h Volume:
1.32M
Relative Volume:
0.61
Market Cap:
$848.84M
Revenue:
-
Net Income/Loss:
$-294.51M
P/E Ratio:
-2.2949
EPS:
-3.56
Net Cash Flow:
$-244.42M
1W Performance:
+17.05%
1M Performance:
-33.63%
6M Performance:
-76.48%
1Y Performance:
-67.08%
1-Day Range:
$7.59
$8.22
1-Week Range:
$6.755
$8.22
52-Week Range:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
8.17 | 848.84M | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
More C-suite changes at Dyne - biocentury.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Enhances Leadership Team with Key Appoin - GuruFocus
Dyne Therapeutics Announces Chief Business Officer and Chief Sci - GuruFocus
Dyne Therapeutics reshapes leadership team ahead of drug launches - Investing.com
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments - GlobeNewswire
Strategic C-Suite Expansion: Dyne Therapeutics Gears Up for Rare Disease Drug Launches - Stock Titan
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dyne Therapeutics Reveals Strategic Compensation Plan: 330K Stock Options Granted - Stock Titan
Dyne wins new Outperform at BMO on prospects for lead drug - MSN
Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m - Yahoo
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
RBC Cuts Price Target on Dyne Therapeutics to $36 From $41, Keeps Outperform, Speculative Risk - MarketScreener
FORCE platform boosts muscle function in dystrophic mice - BioWorld MedTech
Oversold Conditions For Dyne Therapeutics - Nasdaq
FORCE platform leads to Duchenne muscular dystrophy mouse model - BioWorld MedTech
BMO maintains Dyne Therapeutics stock with $50 target By Investing.com - Investing.com Canada
MDA 2025: DYNE-101 improves finger function in DM1 clinical trial - Muscular Dystrophy News
Dyne names Editas’ Erick Lucera CFO - biocentury.com
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path - Benzinga
Sector Update: Health Care Stocks Steady Premarket Friday -March 21, 2025 at 09:24 am EDT - Marketscreener.com
JPMorgan cuts Dyne Therapeutics stock target to $17 from $18 By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - The National Law Review
Dyne Therapeutics Appoints Erick Lucera as Chief Financial Officer - citybiz
Dyne Therapeutics names new CFO ahead of clinical milestones By Investing.com - Investing.com South Africa
Dyne Therapeutics Names Erick Lucera as CFO -March 20, 2025 at 05:36 pm EDT - Marketscreener.com
Dyne Therapeutics Appoints Erick Lucera as CFO - TipRanks
Dyne Therapeutics Announces Appointment of Erick J. Lucera As Chief Financial Officer - Marketscreener.com
Dyne Therapeutics names new CFO ahead of clinical milestones - Investing.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq - GlobeNewswire
New Dyne Therapeutics CFO Secures Major Equity Package Worth 280,600 Shares - StockTitan
Dyne Therapeutics Strengthens Commercial Launch Plans With Strategic CFO Appointment - StockTitan
(DYN) Technical Data - news.stocktradersdaily.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer - The Globe and Mail
Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251 - MSN
Stifel maintains Buy on Dyne Therapeutics with $66 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock - Investing.com
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results - MarketScreener
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank - The Globe and Mail
Dyne Therapeutics Announces New Long-Term Clinical Data - GlobeNewswire
Dyne : Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months - Nasdaq
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - The Manila Times
Dyne Therapeutics Reports Promising Long-Term Data for DYNE-251 in Duchenne Muscular Dystrophy with Plans for Accelerated Approval Submission - Nasdaq
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
Dyne therapeutics chief commercial officer sells $1,733 in stock - Investing.com India
BMO Capital Markets Begins Coverage on Dyne Therapeutics (NASDAQ:DYN) - Defense World
Dyne therapeutics chief commercial officer sells $1,733 in stock By Investing.com - Investing.com Australia
Dyne Therapeutics chief scientific officer sells shares worth $24,501 By Investing.com - Investing.com South Africa
Dyne Therapeutics chief scientific officer sells shares worth $24,501 - Investing.com
GDX Is Looking To Retest 2020 Highs; Gold To 3K Soon? - The Globe and Mail
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):